Westminster Health Forum policy conference: Priorities for medicine access, supply and pricing in the UK *Timing: Morning, Tuesday, 23rd April 2024* ***Taking Place Online***

Agenda subject to change



| 8.30 | Registration WESTMINSTE HEALTH FORU | |
|-------|--|---|
| 9.00 | <u>Chair's opening remarks</u> Rt Hon Lord Hunt of Kings Heath, former Parliamentary Under-Secretary of State for Health (1999 - 2003) | |
| 9.05 | Examining the landscape for medicine accessibility and affordability in the UK Elizabeth Hampson, Partner, Deloitte Questions and comments from the floor | |
| 9.30 | Exploring emerging trends and priorities for improving medicine supply and accessibility Options for mitigating medicine shortages and supply chain disruption Building resilience and stability across the supply chain Maintaining continuity of patient care and access to medicines The role of VPAG Professor Zaheer-Ud-Din Babar, Professor in Medicines and Healthcare, University of Huddersfield Yousaf Ahmad, ICS Chief Pharmacist and Director of Medicines Optimisation, Frimley Health and Care Integrated Care Syster Alison Dennis, Partner, Taylor Wessing Dominic Wake, Head of Corporate Affairs and Market Access, Sandoz UK & Ireland Bushra Effendi, Pharmacist and Clinical Advisor, The Menopause Charity Questions and comments from the floor | m |
| 10.30 | Priorities for economic growth in the UK life sciences sector, and coordinating policy to drive investment and innovation Anusha Foy, Partner, Head of Life Sciences Regulatory Solutions Practice, KPMG Questions and comments from the floor | |
| 10.55 | <u>Chair's closing remarks</u> Rt Hon Lord Hunt of Kings Heath, former Parliamentary Under-Secretary of State for Health (1999 - 2003) | |
| 11.00 | Break | |
| 11.10 | <u>Chair's opening remarks</u> Rt Hon Lord Lansley, former Secretary of State for Health (2010 - 2012) | |
| 11.15 | Examining opportunities for market access and innovation in the VPAG scheme David Watson, Executive Director, Patient Access, Association of the British Pharmaceutical Industry Kim Assender, Director of Commercial Policy and Analysis, Association of the British Pharmaceutical Industry Questions and comments from the floor | |
| 11.40 | Assessing the outlook for advanced therapy medicinal products, regulatory pathways and payment models Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult Questions and comments from the floor | |
| 12.05 | Next steps for implementation of the VPAG scheme Transparency and options for monitoring and reporting patient priorities for the scheme and accessibility to innovative medicine regulatory pathways financial sustainability and value for money in the NHS Dr Scott Purdon, Head of Patient Advocacy, Myeloma UK Leela Barham, Health Economics Researcher and Writer; and Senior Lecturer, University of South Wales Jessamy Baird, General Manager, General Medicines, UK & Ireland, Sanofi Questions and comments from the floor | |
| 12.55 | Chair's and Westminster Health Forum closing remarks | |

Rt Hon Lord Lansley, former Secretary of State for Health (2010 - 2012) Jessica Lear, Westminster Health Forum